Madrigal Pharmaceuticals, Inc.
MDGL
$424.00
$11.772.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3,421.98% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,421.98% | -- | -- | -- | -- |
| Cost of Revenue | 2,914.94% | -- | -- | -- | -- |
| Gross Profit | 3,445.01% | -- | -- | -- | -- |
| SG&A Expenses | 135.65% | 202.22% | 302.29% | 346.87% | 328.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.46% | 63.48% | 78.19% | 79.24% | 64.88% |
| Operating Income | 41.58% | 6.40% | -30.85% | -57.21% | -60.45% |
| Income Before Tax | 44.77% | 11.86% | -24.69% | -49.33% | -54.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.77% | 11.86% | -24.69% | -49.33% | -54.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.77% | 11.86% | -24.69% | -49.33% | -54.78% |
| EBIT | 41.58% | 6.40% | -30.85% | -57.21% | -60.45% |
| EBITDA | 41.77% | 6.57% | -30.74% | -57.19% | -60.48% |
| EPS Basic | 49.62% | 21.83% | -10.89% | -30.31% | -36.76% |
| Normalized Basic EPS | 49.62% | 21.83% | -10.89% | -30.31% | -36.76% |
| EPS Diluted | 49.62% | 21.83% | -10.89% | -30.31% | -36.76% |
| Normalized Diluted EPS | 49.62% | 21.83% | -10.89% | -30.31% | -36.76% |
| Average Basic Shares Outstanding | 10.46% | 13.87% | 13.84% | 14.81% | 12.42% |
| Average Diluted Shares Outstanding | 10.46% | 13.87% | 13.84% | 14.81% | 12.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |